People · Operator
Named in public records as an officer, director or promoter · active 2010–2015 · Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Neomend Inc | — | Other Health Care | Series B | $48.9M | $221.5M | 2010 |
| Carbylan Therapeutics, Inc. | — | Other Health Care | Series A | $15.0M | $80.7M | 2014 |
DAVID M. RENZI at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside DAVID M. RENZI on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Albert Cha | 2 | 9 |
| Jack Nielsen | 1 | 13 |
| Jack B. Nielsen | 1 | 6 |
| Chris Ehrlich | 1 | 6 |
| Guy Nohra | 1 | 5 |
| Mark Weeks | 1 | 4 |
| Keith A. Katkin | 1 | 3 |
| Guy P. Nohra | 1 | 3 |
| Abhi Acharya | 1 | 3 |
| Timothy Mills | 1 | 3 |
| Steven Basta | 1 | 3 |
| Alex Barkas | 1 | 3 |
| Steven L. Basta | 1 | 2 |
| Albert L. Cha | 1 | 2 |
| Timothy M. Mills | 1 | 2 |
| David Renzi | 1 | 2 |
| Alex M. Barkas | 1 | 1 |
| Kevin M. Cousins | 1 | 1 |
| Mike M. Nagel | 1 | 1 |
| Wade M. King | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.